title: Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
abstract: The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.
authors.affiliation: Department of Internal Medicine, School of Medicine, Department of Veteran's Affairs Medical Center, Wayne State University, Detroit, Michigan 48201, USA. gkaatz@juno.com
authors.forename: G W
authors.initials: GW
authors.lastname: Kaatz
authors.forename: S M
authors.initials: SM
authors.lastname: Seo
authors.forename: J R
authors.initials: JR
authors.lastname: Aeschlimann
authors.forename: H H
authors.initials: HH
authors.lastname: Houlihan
authors.forename: R C
authors.initials: RC
authors.lastname: Mercier
authors.forename: M J
authors.initials: MJ
authors.lastname: Rybak
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D006020:Glycopeptides; D007668:Kidney / Q000382:microbiology; D000077427:Lipoglycopeptides; D008297:Male; D016106:Methicillin Resistance; D011817:Rabbits; D013154:Spleen / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D014640:Vancomycin / Q000097:blood / Q000627:therapeutic use / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D014640:Vancomycin; C100708:oritavancin